{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wu S"],"funding":["Natural Science Foundation of Hubei Province","Fundamental Research Funds for the Central Universities South-Central MinZu University","Open Fund of Hubei Key Laboratory of Resources and Chemistry of Chinese Medicine and Hubei Provincial Department of Education Guiding Program","Natural Science Foundation Project of Hubei Provincial Administration of Traditional Chinese Medicine","State Administration of Traditional Chinese Medicine High-level Key Discipline Construction Project of Traditional Chinese Medicine - Chinese Medicine Resource Science"],"pagination":["56"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12370617"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["15(1)"],"pubmed_abstract":["Modern pharmacology has found that both Realgar and Coptis chinensis can induce apoptosis in tumor cells, and traditional Chinese medicine theory suggests the possibility of combining the two, however, the specific mechanisms involved have not been elucidated. This study investigated the therapeutic mechanism of the Realgar-Coptis chinensis drug pair (RCCD) against hepatocellular carcinoma (HCC) by identifying its key active compounds and targets. Through integrated LC-MS analysis, transcriptomics, network pharmacology, and bioinformatics, we identified the mechanism of action, key bioactive compounds, and core targets. Molecular docking, molecular dynamics simulations, and microscale thermophoresis (MST) validated the binding affinity between key compounds and core targets. TIMER2.0 datab"],"journal":["Natural products and bioprospecting"],"pubmed_title":["Dual inhibition of FAS and HAS2/3 by 4-MU in Realgar-Coptis chinensis unveils a metabolic checkpoint for liver cancer therapy."],"pmcid":["PMC12370617"],"funding_grant_id":["2024AFD252","Medicinal Mineralogy","ZY2025D020","B2023089","CZZ24017"],"pubmed_authors":["Gui C","Deng D","Zheng X","Liao F","Mei H","Wang C","Wu S","Wang Y","Zheng G","Xiang M"],"additional_accession":[]},"is_claimable":false,"name":"Dual inhibition of FAS and HAS2/3 by 4-MU in Realgar-Coptis chinensis unveils a metabolic checkpoint for liver cancer therapy.","description":"Modern pharmacology has found that both Realgar and Coptis chinensis can induce apoptosis in tumor cells, and traditional Chinese medicine theory suggests the possibility of combining the two, however, the specific mechanisms involved have not been elucidated. This study investigated the therapeutic mechanism of the Realgar-Coptis chinensis drug pair (RCCD) against hepatocellular carcinoma (HCC) by identifying its key active compounds and targets. Through integrated LC-MS analysis, transcriptomics, network pharmacology, and bioinformatics, we identified the mechanism of action, key bioactive compounds, and core targets. Molecular docking, molecular dynamics simulations, and microscale thermophoresis (MST) validated the binding affinity between key compounds and core targets. TIMER2.0 datab","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Aug","modification":"2026-04-08T09:11:37.707Z","creation":"2026-04-08T00:47:09.521Z"},"accession":"S-EPMC12370617","cross_references":{"pubmed":["40839202"],"doi":["10.1007/s13659-025-00540-9"]}}